SIDE EFFECTS
GLP-1 drugs linked to elevated risk of eye disease
People with diabetes taking GLP-1 drugs had a low but elevated risk of an age-related eye disease that can sometimes lead to blindness, a new observational study concludes.
The research, published Thursday in JAMA Ophthalmology, found that after one year, more than twice as many people on GLP-1 drugs developed neovascular age-related macular degeneration compared to similar people who were not taking the drugs. The risk was 0.2% in people taking GLP-1s and 0.1% in those who didn’t.
Famous for their success in helping people lose weight, GLP-1 drugs were originally intended to control their blood sugar. But as their use has exploded, various eye problems have been reported, including abnormal blood vessel growth. STAT’s Elizabeth Cooney has more about these powerful medications and their possible side effects.
FOUNTAIN OF YOUTH
Sadly, Red Bull does not give you wings
To the dismay of line cooks and bodybuilders everywhere, a new report found that taurine — an amino acid abundant in plants, animals and energy drinks — was found to be an unreliable biomarker for aging.
Taurine has long been a darling of longevity seekers, but results published Thursday have cast doubt on a 2023 study that made the amino acid a staple ingredient for biohackers searching for anti-aging elements (a la tech mogul Bryan Johnson). The new study data showed that taurine rises with age, pulling data from 32 monkeys, 39 mice, one cohort of 742 humans, one cohort of 159 humans, and another cohort of 72 humans.
The data are a reminder of just how messy and complicated longevity studies can be, and how elusive treatments, or even just reliable markers, for aging remain. STAT’s Jason Mast has the study's full readout.
FIRST OPINION
At-home sexual assault kits come with legal, health risks
The Food and Drug Administration recently approved the first at-home cervical cancer screening test in May, marking a significant shift toward accessible, patient-driven health care. But the agency’s decision may revive the debate over at-home sexual assault kits, at a time when states and companies selling these kits are battling over their legality, writes Rachell Ekroos, a forensic nursing expert.
The concept of at-home sexual assault evidence collection kits emerged in the late 2010s at the height of the “Me Too” movement, when companies began offering them as a way to empower survivors to collect forensic evidence privately and on their own terms. But a legal fight over their accuracy soon emerged, and advocacy groups worried about the lack of oversight, quality control, and linkage to support options for the survivor. To understand why Ekroos is worried that the newly approved at-home cervical screening tests will revive the movement for at-home sexual assault kits, read on.